GTHA – GeneThera, Inc.
Stock Guru Profile GeneThera, Inc. (OTCBB:GTHA)
GeneThera and Leading Italian Research Institute Finalize Collaboration Agreement on Mad-Cow and Other Animal Diseases
Dr. Tony Milici
Chairman of the Board, President & CEO
Dr. Milici is a Ph.D. in Experimental Hematology and M.D. in Medicine and Surgery, receiving degrees from University of Rome (Italy) and Stanford University.
His specialties include: molecular biology/biotechnology, Gene Therapy/Molecularly Oncology and Molecular. He has had extensive post-graduate training that includes a fellowship in the Department of Clinical Immunology with the University of Texas M.D. Anderson Cancer Center and Visiting Fellow at University of Rome’s Laboratory of Cellular Immunology and Biochemistry.
Among his post-graduate activities, Dr. Milici was an Assistant Professor at the Medical College of Georgia’s Department of Pharmacology and Toxology as well as an Assistant Biochemist in the Department of Molecular Pathology at the University of Texas M.D. Anderson Cancer Center in Houston, Texas. Prior to founding GeneThera, Inc., Dr. Milici was President and CEO of Genetrans, Inc. based in Augusta, Georgia, a diagnostics laboratory. For Dr. Milici, GeneThera is a realization of an ambition to demonstrate the commercial potential of molecular biotechnology.
What Is Mad Cow Disease and Why Does It Matter?
Dr. Milici took the time to explain BSE or Mad Cow Disease or bovine spongiform encephalopathy to Stock Guru.
The brain-wasting disorder infected more than 180,000 cows and was blamed for more than 150 human deaths during a European outbreak that peaked in 1993. Humans can get a related disease, variant Creutzfeldt-Jakob Disease, by eating meat contaminated with mad cow.
Bovine spongiform encephalopathy, or mad cow disease, is a degenerative nerve disease in cattle that can lead to the fatal Creutzfeld-Jakob disease in humans. GeneThera’s BSE live animal test can also be use to diagnose variant Creutzfeldt-Jakob Disease. Since nobody knows the extent of the infection in human it is very critical to be able to test the blood of potentially variant Creutzfeldt-Jakob Disease infected patients.
Scientist have now determined that Creutzfeldt-Jakob Disease can be transmitted through contact with contaminated blood. It is therefore of paramount importantce to be able to screen blood supply banks for the presence of Creutzfeldt-Jakob Disease. How Serious is Creutzfeldt-Jakob Disease?
Very.
From the Independent Newspapers Ireland Ltd (6/23/06) comes the following information:
The number of people infected with Creutzfeldt-Jakob Disease could be far higher than thought because of a longer incubation period than previously assumed, British scientists said in June of 2006. They believe the time between infection with bovine spongiform encephalopathy (BSE) and developing variant Creutzfeldt-Jakob disease (vCJD) could be more than 50 years. The authors believe the incubation period for BSE prions in humans could be even longer than that seen in kuru because infection between different species typically takes longer than within the same species.
Prof Collinge said variant Creutzfeldt-Jakob disease patients identified so far “could represent a distinct genetic subpopulation with unusually short incubation periods for BSE. A human BSE epidemic may be multiphasic, and recent estimates of the size of the variant Creutzfeldt-Jakob disease epidemic based on uniform genetic susceptibility could be substantial underestimations.”
According to figures from the variant Creutzfeldt-Jakob disease surveillance unit in Edinburgh, 2,079 suspected cases of all types of CJD have been referred to them since 1990.
From the Birmingham Post (10/1/06) comes the following information:
But doctors believe nearly 4,000 more could be infected -although most have not yet developed symptoms. Latest research has found thousands more could develop variant-Creutzfeldt-Jakob Disease because the incubation period could last into the middle of this century, far longer than previously thought.
And that means children born in the 1980s will have to live with the threat of developing variant Creutzfeldt-Jakob disease for the rest of their lives. Last night Frances Hall, from the Human BSE Foundation, a victim support group, said: “We are sitting on a timebomb. “It’s so sad to think that other families could be left devastated in the way that mine and the other 120 in our group have been.”
This year marks the 20th anniversary since the Government identified BSE as a new disease in cows. Yet it took a further 10 years before the then British health secretary, Stephen Dorrell, admitted that government advisers believed that BSE was linked to variant Creutzfeldt-Jakob disease.
It is believed that BSE was caused by cows being given cheap feed created from the carcasses of sheep infected with a similar illness, called scarpie, in 1986. By 1996 the incurable brain disease had killed 10 people and it was feared that it could turn into an epidemic.
Dr. Milici is a vegetarian!
Stay tuned for this very important story with more twists and turns than a Colorado mountain switchback. Also, and very importantly, we will examine other focuses this company has.
About GeneThera, Inc. GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company’s proprietary diagnostic solution is based on a genetic expression assay, GEA(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johnne’s Disease, diseases affecting cattle worldwide.
About IZSLER Istituto Zooprofilattico Sperimentale della Lombardia e dell’Emilia Romagna (IZSLER),(www.bs.izs.it), offers a broad range of services in the Public Veterinary sectors in particular, Food Safety to the Veterinary Services, Breeders and Consumers. Its functions today can be described as those of a Technical-Scientific Body providing services as required of it by national and regional law. At the present, IZSLER employs over 600 persons, 90 of them are graduated scientists (veterinarians, biologists and chemists). On a regional basis (Lombardia and Emilia Romagna), IZSLER performs diagnosis for a variety of viral infectious diseases of ruminants, pigs, horses, poultry and other species of economic interest (rabbits, fishes, bees….), and microbiological and chemical analysis on foodstuffs of animal origin destined for human consumption and on food resources for animals.
“Safe Harbor” Statement: Certain statements in this release are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company’s ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.
Forward Loooking Statement: A number of statements contained in this report are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com .
Disclosure: Pentony Enterprises LLC: was compensated 500,000 free trading shares from a non-controlling third party for profile coverage. Pentony Enterprises is not a registered investment advisers or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.